{"@context":"https://schema.org","@graph":[{"@id":"https://thehippiescientist.net/compounds/tirzepatide/#entity","@type":["ChemicalSubstance","MolecularEntity"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"evidence tier","value":"Editorial grade not demonstrated by recorded studies"},{"@type":"PropertyValue","propertyID":"AI entity completeness score","value":34}],"category":"Dual GIP/GLP-1 receptor agonist (prescription drug)","description":"Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved as Mounjaro and Zepbound, showing the largest average weight-loss effect of any approved obesity drug to date (up to ~22.5% body weight at 72 weeks in SURMOUNT-1) and superior HbA1c reduction versus semaglutide in a head-to-head trial.","identifier":[{"@type":"PropertyValue","propertyID":"THS entity id","value":"ths:compound:tirzepatide"},{"@type":"PropertyValue","propertyID":"THS slug","value":"tirzepatide"}],"mentions":[{"@id":"https://thehippiescientist.net/compounds/semaglutide/#entity","@type":["ChemicalSubstance","Thing"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"relationship type","value":"related-to"}],"name":"Semaglutide","url":"https://thehippiescientist.net/compounds/semaglutide/"}],"name":"Tirzepatide","subjectOf":{"@id":"https://thehippiescientist.net/compounds/tirzepatide/#evidence-data"},"url":"https://thehippiescientist.net/compounds/tirzepatide/"},{"@id":"https://thehippiescientist.net/compounds/tirzepatide/#evidence-data","@type":"Article","about":{"@id":"https://thehippiescientist.net/compounds/tirzepatide/#entity"},"author":{"@type":"Person","name":"Willie B. Randolph III","url":"https://thehippiescientist.net/info/author/","@id":"https://thehippiescientist.net/info/author/#person","affiliation":{"@id":"https://thehippiescientist.net/#organization"}},"dateModified":"2026-06-30","dateReviewed":"2026-06-30","description":"Tirzepatide is a dual GIP/GLP-1 receptor agonist, FDA-approved as Mounjaro and Zepbound, showing the largest average weight-loss effect of any approved obesity drug to date (up to ~22.5% body weight at 72 weeks in SURMOUNT-1) and superior HbA1c reduction versus semaglutide in a head-to-head trial.","headline":"Tirzepatide evidence, safety, and entity data","mainEntity":{"@id":"https://thehippiescientist.net/compounds/tirzepatide/#entity"},"mentions":[{"@id":"https://thehippiescientist.net/compounds/semaglutide/#entity","@type":["ChemicalSubstance","Thing"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"relationship type","value":"related-to"}],"name":"Semaglutide","url":"https://thehippiescientist.net/compounds/semaglutide/"}],"publisher":{"@type":"Organization","name":"The Hippie Scientist","url":"https://thehippiescientist.net","@id":"https://thehippiescientist.net/#organization"},"url":"https://thehippiescientist.net/compounds/tirzepatide/"}]}